Veterinary Medicines

Versican Plus DHP lyophilisate and solvent for suspension for injection for dogs

Authorised
  • Canine parvovirus, type 2b, strain CPV-2b Bio 12/B, Live
  • Canine adenovirus 2, strain CAV-2-Bio 13, Live
  • Canine distemper virus, strain CDV Bio 11/A, Live
Download as PDF

Product identification

Medicine name:
Versican Plus DHP lyophilisate and solvent for suspension for injection for dogs
Versican Plus DHP
Active substance:
  • Canine parvovirus, type 2b, strain CPV-2b Bio 12/B, Live
  • Canine adenovirus 2, strain CAV-2-Bio 13, Live
  • Canine distemper virus, strain CDV Bio 11/A, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Canine parvovirus, type 2b, strain CPV-2b Bio 12/B, Live
    19953.00
    50% tissue culture infectious dose
    /
    1.00
    Dose
  • Canine adenovirus 2, strain CAV-2-Bio 13, Live
    3981.00
    50% tissue culture infectious dose
    /
    1.00
    Dose
  • Canine distemper virus, strain CDV Bio 11/A, Live
    1259.00
    50% tissue culture infectious dose
    /
    1.00
    Dose
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AD02
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Germany
Available in:
  • Germany
Package description:
  • (ID2): 1 Box with (50 Vial (Glass) with 1 Dose and 50 Vial (Glass) with 1 ml) (50.0 Dose, 50.0 ml)
  • (ID1): 1 Box with (25 Vial (Glass) with 1 Dose and 25 Vial (Glass) with 1 ml) (25.0 Dose, 25.0 ml)

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Zoetis Deutschland GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • Bioveta a.s.
Responsible authority:
  • Paul-Ehrlich-Institut
Authorisation number:
  • PEI.V.11783.01.1
Date of authorisation status change:
Reference member state:
  • Germany
Procedure number:
  • DE/V/0267/001
Concerned member states:
  • Belgium
  • Bulgaria
  • Cyprus
  • Denmark
  • Finland
  • Greece
  • Hungary
  • Italy
  • Luxembourg
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
German (PDF)
Published on: 6/11/2025
Download

2613563-paren-20251101.pdf

English (PDF)
Published on: 8/12/2025
Download

2613563-paren-20170427.pdf.pdf

English (PDF)
Published on: 17/09/2024
Download